Signalling networks regulating cyclooxygenase-2

被引:444
作者
Tsatsanis, Christos [1 ]
Androulidaki, Ariadne [1 ]
Venihaki, Maria [1 ]
Margioris, Andrew N. [1 ]
机构
[1] Univ Crete, Sch Med, Dept Clin Chem Biochem, GR-71003 Iraklion, Crete, Greece
关键词
COX-2; MAPK; inflammation; cancer; NSAID;
D O I
10.1016/j.biocel.2006.03.021
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cyclooxygenease-2 (COX-2) is the key enzyme regulating the production of prostaglandins, central mediators of inflammation. The expression of cyclooxygenease-2 is induced by several extra cellular signals including pro-inflammatory and growth-promoting stimuli. All signals converge to the activation of mitogen-activated protein kinases (MAPK) that regulate cyclooxygenease-2 mRNA levels both at the transcriptional and post-transcriptional level. The machinery appears to be highly specialized involving activation of distinct signalling molecules depending on the type of extracellular stimulus. Expression of cyclooxygenease-2 mRNA is regulated by several transcription factors including the cyclic-AMP response element binding protein (CREB), nuclear factor kappa B (NFkB) and the CCAAT-enhancer binding protein (C/EBP). Cyclooxygenease-2 is also affected post-transcriptionaly, at the level of mRNA stability. Finally, cyclooxygenease-2 can be affected directly at its enzymatic activity by nitric oxide and nitric oxide synthase (NOS). Each step of cyclooxygenease-2 regulation can be used as potential therapeutic target. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1654 / 1661
页数:8
相关论文
共 56 条
[1]   Inhibition of p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase decreases UVB-induced activator protein-1 and cyclooxygenase-2 in a SKH-1 hairless mouse model [J].
Bachelor, MA ;
Cooper, SJ ;
Sikorski, ET ;
Bowden, GT .
MOLECULAR CANCER RESEARCH, 2005, 3 (02) :90-99
[2]   Mechanisms for the prevention of gastrointestinal cancer:: The role of prostaglandin E2 [J].
Backlund, MG ;
Mann, JR ;
DuBois, RN .
ONCOLOGY, 2005, 69 :28-32
[3]   Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [J].
Bresalier, RS ;
Sandler, RS ;
Quan, H ;
Bolognese, JA ;
Oxenius, B ;
Horgan, K ;
Lines, C ;
Riddell, R ;
Morton, D ;
Lanas, A ;
Konstam, MA ;
Baron, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) :1092-1102
[4]   Cyclooxygenase-2 promotes early atherosclerotic lesion formation in apoE-deficient and C57BL/6 mice [J].
Burleigh, ME ;
Babaev, VR ;
Yancey, PG ;
Major, AS ;
McCaleb, JL ;
Oates, JA ;
Marrow, JD ;
Fazio, S ;
Linton, MF .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2005, 39 (03) :443-452
[5]   Role of mitogen-activated protein kinase cascades in mediating lipopolysaccharide-stimulated induction of cyclooxygenase-2 and IL-1β in RAW264 macrophages [J].
Caivano, M ;
Cohen, P .
JOURNAL OF IMMUNOLOGY, 2000, 164 (06) :3018-3025
[6]   Transcriptional regulation of cyclooxygenase-2 in response to proteasome inhibitors involves reactive oxygen species-mediated signaling pathway and recruitment of CCAAT/enhancer-binding protein δ and CREB-binding protein [J].
Chen, JJ ;
Huang, WC ;
Chen, CC .
MOLECULAR BIOLOGY OF THE CELL, 2005, 16 (12) :5579-5591
[7]   Induction of vascular endothelial growth factor by nitric oxide in human glioblastoma and hepatocellular carcinoma cells [J].
Chin, K ;
Kurashima, Y ;
Ogura, T ;
Tajiri, H ;
Yoshida, S ;
Esumi, H .
ONCOGENE, 1997, 15 (04) :437-442
[8]   Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention [J].
Chun, KS ;
Surh, YJ .
BIOCHEMICAL PHARMACOLOGY, 2004, 68 (06) :1089-1100
[9]   Role of p300 and PCAF in regulating cyclooxygenase-2 promoter activation by inflammatory mediators [J].
Deng, WG ;
Zhu, Y ;
Wu, KK .
BLOOD, 2004, 103 (06) :2135-2142
[10]   Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells [J].
Dixon, DA ;
Tolley, ND ;
King, PH ;
Nabors, LB ;
McIntyre, TM ;
Zimmerman, GA ;
Prescott, SM .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 108 (11) :1657-1665